Literature DB >> 24157906

Comparison of HIV DNA and RNA in gut-associated lymphoid tissue of HIV-infected controllers and noncontrollers.

Hiroyu Hatano1, Ma Somsouk, Elizabeth Sinclair, Kara Harvill, Lee Gilman, Michelle Cohen, Rebecca Hoh, Peter W Hunt, Jeffrey N Martin, Joseph K Wong, Steven G Deeks, Steven A Yukl.   

Abstract

OBJECTIVES: HIV-infected controllers have provided novel insights into mechanisms of viral control. We investigated the degree to which HIV DNA and RNA are present in gut-associated lymphoid tissue (GALT) of controllers.
DESIGN: Cross-sectional cohort study.
METHODS: Colorectal biopsy pieces were obtained from five untreated noncontrollers, five ART-suppressed patients, and nine untreated controllers.
RESULTS: Rectal HIV DNA was lower in controllers (median 496 copies/10(6) CD4 T cells) than in untreated noncontrollers (117483 copies/10(6) CD4+ T cells, P = 0.001) and ART-suppressed patients (6116 copies/10(6) CD4 T cells, P = 0.004). Similarly, rectal HIV RNA was lower in controllers (19 copies/10(6) CD4 T cells) than in noncontrollers (15210 copies/10(6) CD4+ T cells, P = 0.001) and ART-suppressed patients (1625 copies/10(6) CD4+ T cells, P = 0.0599). Rectal HIV RNA/DNA ratios were not statistically different between the three groups.
CONCLUSION: Despite being able to maintain very low plasma HIV RNA levels in the absence of antiretroviral therapy (ART), HIV-infected controllers have readily measurable levels of HIV DNA and RNA in GALT. As expected, controllers had lower rectal HIV DNA and RNA compared with untreated noncontrollers and ART-suppressed individuals. Compared with the mechanisms of 'natural' viral control of controllers, long-term ART does not reduce the total HIV reservoir to the level of controllers.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24157906      PMCID: PMC4143147          DOI: 10.1097/QAD.0b013e328362692f

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  29 in total

1.  Natural history of serum HIV-1 RNA levels in 330 patients with a known date of infection. The SEROCO Study Group.

Authors:  J B Hubert; M Burgard; E Dussaix; C Tamalet; C Deveau; J Le Chenadec; M L Chaix; E Marchadier; J L Vildé; J F Delfraissy; L Meyer
Journal:  AIDS       Date:  2000-01-28       Impact factor: 4.177

2.  Replication-competent HIV strains infect HIV controllers despite undetectable viremia (ANRS EP36 study).

Authors:  Aurelia Lamine; Anne Caumont-Sarcos; Marie-Laure Chaix; Asier Saez-Cirion; Christine Rouzioux; Jean-François Delfraissy; Gianfranco Pancino; Olivier Lambotte
Journal:  AIDS       Date:  2007-05-11       Impact factor: 4.177

3.  Plasma human immunodeficiency virus RNA below 40 Copies/mL is rare in untreated persons even in the first years of infection.

Authors:  J J Lefrère; M Mariotti; L Morand-Joubert; M Thauvin; F Roudot-Thoraval
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

4.  Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment.

Authors:  Brinda Emu; Elizabeth Sinclair; David Favre; Walter J Moretto; Priscilla Hsue; Rebecca Hoh; Jeffrey N Martin; Douglas F Nixon; Joseph M McCune; Steven G Deeks
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

5.  Highly sensitive methods for quantitation of human immunodeficiency virus type 1 RNA from plasma, cells, and tissues.

Authors:  M Fischer; W Huber; A Kallivroussis; P Ott; M Opravil; R Lüthy; R Weber; R W Cone
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

6.  HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication.

Authors:  Olivier Lambotte; Faroudy Boufassa; Yoann Madec; Ahn Nguyen; Cécile Goujard; Laurence Meyer; Christine Rouzioux; Alain Venet; Jean-François Delfraissy
Journal:  Clin Infect Dis       Date:  2005-08-30       Impact factor: 9.079

7.  Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors.

Authors:  Joel N Blankson; Justin R Bailey; Seema Thayil; Hung-Chih Yang; Kara Lassen; Jun Lai; Shiv K Gandhi; Janet D Siliciano; Thomas M Williams; Robert F Siliciano
Journal:  J Virol       Date:  2006-12-06       Impact factor: 5.103

8.  Natural controlled HIV infection: preserved HIV-specific immunity despite undetectable replication competent virus.

Authors:  Nico Kloosterboer; Paul H P Groeneveld; Christine A Jansen; Teun J K van der Vorst; Fransje Koning; Carel N Winkel; Ashley J Duits; Frank Miedema; Debbie van Baarle; Ronald P van Rij; Kees Brinkman; Hanneke Schuitemaker
Journal:  Virology       Date:  2005-08-15       Impact factor: 3.616

9.  Optimization of methods to assess human mucosal T-cell responses to HIV infection.

Authors:  Barbara L Shacklett; Otto Yang; Mary Ann Hausner; Julie Elliott; Lance Hultin; Charles Price; Marie Fuerst; Jose Matud; Patricia Hultin; Catherine Cox; Javier Ibarrondo; Johnson T Wong; Douglas F Nixon; Peter A Anton; Beth D Jamieson
Journal:  J Immunol Methods       Date:  2003-08       Impact factor: 2.303

10.  Human immunodeficiency virus type 1 RNA Levels in different regions of human brain: quantification using real-time reverse transcriptase-polymerase chain reaction.

Authors:  Adarsh M Kumar; Irina Borodowsky; Benny Fernandez; Louis Gonzalez; Mahendra Kumar
Journal:  J Neurovirol       Date:  2007-06       Impact factor: 2.643

View more
  27 in total

Review 1.  The Alphabet Soup of HIV Reservoir Markers.

Authors:  Radwa R Sharaf; Jonathan Z Li
Journal:  Curr HIV/AIDS Rep       Date:  2017-04       Impact factor: 5.071

Review 2.  Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications.

Authors:  Véronique Avettand-Fènoël; Laurent Hocqueloux; Jade Ghosn; Antoine Cheret; Pierre Frange; Adeline Melard; Jean-Paul Viard; Christine Rouzioux
Journal:  Clin Microbiol Rev       Date:  2016-10       Impact factor: 26.132

Review 3.  Very early combination antiretroviral therapy in infants: prospects for cure.

Authors:  Kaitlin Rainwater-Lovett; Katherine Luzuriaga; Deborah Persaud
Journal:  Curr Opin HIV AIDS       Date:  2015-01       Impact factor: 4.283

Review 4.  CRISPR/Cas9 and Genome Editing for Viral Disease-Is Resistance Futile?

Authors:  Harshana S De Silva Feelixge; Daniel Stone; Pavitra Roychoudhury; Martine Aubert; Keith R Jerome
Journal:  ACS Infect Dis       Date:  2018-03-21       Impact factor: 5.084

5.  Parallel studies of mucosal immunity in the reproductive and gastrointestinal mucosa of HIV-infected women.

Authors:  Uma Shanmugasundaram; J William Critchfield; Linda C Giudice; Karen Smith-McCune; Ruth M Greenblatt; Barbara L Shacklett
Journal:  Am J Reprod Immunol       Date:  2020-05-08       Impact factor: 3.886

Review 6.  Towards an HIV-1 cure: measuring the latent reservoir.

Authors:  Katherine M Bruner; Nina N Hosmane; Robert F Siliciano
Journal:  Trends Microbiol       Date:  2015-03-05       Impact factor: 17.079

7.  Safety, Immune, and Antiviral Effects of Pegylated Interferon Alpha 2b Administration in Antiretroviral Therapy-Suppressed Individuals: Results of Pilot Clinical Trial.

Authors:  Emmanouil Papasavvas; Livio Azzoni; Amélie Pagliuzza; Mohamed Abdel-Mohsen; Brian N Ross; Matthew Fair; Bonnie J Howell; Daria J Hazuda; Nicolas Chomont; Qingsheng Li; Karam Mounzer; Jay R Kostman; Pablo Tebas; Luis J Montaner
Journal:  AIDS Res Hum Retroviruses       Date:  2021-01-29       Impact factor: 1.723

8.  Tissue Pharmacologic and Virologic Determinants of Duodenal and Rectal Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution in HIV-Infected Patients Initiating Antiretroviral Therapy.

Authors:  David M Asmuth; Corbin G Thompson; Tae-Wook Chun; Zhong-Min Ma; Surinder Mann; Talia Sainz; Sergio Serrano-Villar; Netanya S Utay; Juan Carlos Garcia; Paolo Troia-Cancio; Richard B Pollard; Christopher J Miller; Alan Landay; Angela D Kashuba
Journal:  J Infect Dis       Date:  2017-10-17       Impact factor: 5.226

9.  Elite suppressors have low frequencies of intact HIV-1 proviral DNA.

Authors:  Abena Kr Kwaa; Caroline C Garliss; Kristen D Ritter; Gregory M Laird; Joel N Blankson
Journal:  AIDS       Date:  2020-03-15       Impact factor: 4.632

10.  Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers.

Authors:  Hiroyu Hatano; Steven A Yukl; April L Ferre; Erin H Graf; Ma Somsouk; Elizabeth Sinclair; Mohamed Abdel-Mohsen; Teri Liegler; Kara Harvill; Rebecca Hoh; Sarah Palmer; Peter Bacchetti; Peter W Hunt; Jeffrey N Martin; Joseph M McCune; Russell P Tracy; Michael P Busch; Una O'Doherty; Barbara L Shacklett; Joseph K Wong; Steven G Deeks
Journal:  PLoS Pathog       Date:  2013-10-10       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.